Dimerix Ltd
- Country
- Ownership
- -
- Employees
- 12
- Market Cap
- -
- Introduction
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
DXB Secures $107M Licensing Deal in Japan, Awaits Phase 3 Results
DXB has signed a significant $107M licensing deal in Japan for its FSGS clinical trial, marking its third such agreement before Phase 3 results are published. The company is on the brink of potentially securing accelerated FDA approval, with key milestones and results expected by August 2025.
© Copyright 2025. All Rights Reserved by MedPath